IL1B and neoplasm: The IL-1β is the main cytokine produced both peripherally and centrally in response to tumor development, but its genetic deletion does not alleviate fatigue signs in different preclinical models, suggesting that IL-1β might be the initial driver or regulator of some symptoms but not the unique therapeutic target (Olson, et al., 2021b).